Tetravalent antibodies are more potent and efficacious erythropoiesis‐stimulating agents than erythropoietin in vivo
Protein Science · 2026
DOI: 10.1002/pro.70462 ↗Kurz gefasst
Fachartikel in der Zeitschrift Protein Science, 2026. Verfasst von Jarrett J Adams und 20 weiteren Autor:innen. Beteiligte Einrichtung: Anvil Institute for Systems Biologics, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Receptors, Erythropoietin, Erythropoietin, Erythropoiesis, Hematinics. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Charles Pak Foundation, NIDDK NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Recent studies have shown that tetravalent antibodies are potent and efficacious agonists of the erythropoietin (EPO) receptor (EPOR) both in vitro and in vivo. To identify antibody‐based erythropoiesis‐stimulating agents (ESAs) with therapeutic potential, we evaluated various tetravalent antibody formats for EPOR agonism and key biophysical properties necessary for biologic drug development. We identified two distinct tetravalent antibody formats that strongly stimulated the growth of UT7/Epo cells, which rely on EPOR signaling for proliferation. Moreover, one of these formats exhibited ideal biophysical characteristics for drug development. This format consisted of a diabody (Db) and two antigen‐binding fragment (Fab) arms fused to the N‐ and C‐termini of an Fc domain, respectively, to form a tetravalent Db‐Fc‐Fab (EPRA‐0322). In a mouse model expressing the human EPOR, EPRA‐0322 induced erythropoiesis with greater potency, efficacy, and duration than darbepoetin, a hyperglycosylated EPO currently used in clinical practice. These findings highlight tetravalent antibodies, and the Db‐Fc‐Fab format in particular, as promising next‐generation ESAs suitable for large‐scale production and clinical use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Anvil Institute for Systems Biologics, Toronto, Ontario, Canada.
- EPOK Therapeutics, Toronto, Ontario, Canada.
- Simisco Biosciences, Hayward, California, USA.
- Département de Biochimie, Université de Montréal, Montréal, Québec, Canada.
- Departments of Internal Medicine and Physiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Icosagen, Tartu, Estonia.
Förderung
- Charles Pak Foundation
- NIDDK NIH HHS
- NIGMS NIH HHS
- Canada Foundation for Innovation
- NIH HHS
- NHLBI NIH HHS
- Center of Mineral Metabolism Endowed Professor Collaborative Research Support Grant
- CIHR
Zitieren
APA
Adams, J. J., Blazer, L. L., Chung, J., Karimi, M., Davidson, T., Blair, B., Waddle, C., Hokanson, C. A., Bruce, H. A., Singer, A. U., Tombak, E. M., Gildemann, K., Tamberg, N., Kiiver, K., Ustav, M., Ma, Y., Colombo, L., Huang, L. J., Michnick, S. W., …, & Sidhu, S. S. (2026). Tetravalent antibodies are more potent and efficacious erythropoiesis‐stimulating agents than erythropoietin in vivo. Protein Science. https://doi.org/10.1002/pro.70462
Vancouver
Adams JJ, Blazer LL, Chung J, Karimi M, Davidson T, Blair B, et al. Tetravalent antibodies are more potent and efficacious erythropoiesis‐stimulating agents than erythropoietin in vivo. Protein Science. 2026. doi:10.1002/pro.70462
BibTeX
@article{Adams2026,
author = {Adams, Jarrett J and Blazer, Levi L and Chung, Jacky and Karimi, Minoo and Davidson, Taylor and Blair, Bailey and Waddle, Carlos and Hokanson, Craig A and Bruce, Heather A and Singer, Alexander U and Tombak, Eva-Maria and Gildemann, Kiira and Tamberg, Nele and Kiiver, Kaja and Ustav, Mart and Ma, Yue and Colombo, Luigi and Huang, Lily Jun-Shen and Michnick, Stephen W and Moe, Orson W and Sidhu, Sachdev S},
title = {Tetravalent antibodies are more potent and efficacious erythropoiesis‐stimulating agents than erythropoietin in vivo},
journal = {Protein Science},
year = {2026},
doi = {10.1002/pro.70462}
}
EUVIMED